Press Release

                       Dialysis Corporation of America
                                   Announces
                           Share Repurchase Program

Linthicum, Maryland, April 13, 2009 - Dialysis Corporation of America
(NASDAQ-DCAI) announced that its Board of Directors has approved a stock
repurchase program, effective April 13, 2009. Under the program, the company
is authorized to repurchase up to $3 million of its outstanding shares of
common stock from time to time, depending on market conditions, share price
and other factors.

The stock purchases will be made out of available cash in open market
transactions at the prevailing market price or through privately negotiated
transactions.

"This stock repurchase program underscores the level of confidence we have in
our company and is aligned with our commitment to deliver long-term
shareholder value," said Thomas K. Langbein, Chairman of the Board.

The duration of the repurchase program is open-ended but may be suspended or
discontinued at any time in the discretion of the company's management
without prior notice. As of April 13, 2009, the company had approximately 9.6
million shares of common stock outstanding.

Dialysis Corporation of America owns and operates freestanding kidney
hemodialysis centers located in Georgia, Maryland, New Jersey, Ohio,
Pennsylvania, South Carolina, and Virginia, and provides in-hospital dialysis
services on a contract basis to certain hospitals located in the those
states.  The company provides patients with their choice of a full range of
quality in-center, acute or at-home hemodialysis services.

This release contains forward-looking statements that are subject to risks
and uncertainties that could affect the business and prospects of the company
and cause actual results and plans to differ materially from those
anticipated. Those factors include, but are not limited to, increases in
interest rates, the possible need for and availability of additional
financing, the company's satisfying the covenants and conditions of its
credit facility, certain delays beyond the company's control with respect to
future business events, the highly competitive environment in the
establishment and operation of dialysis centers, the ability to develop or
acquire additional dialysis facilities, whether patient bases of the
company's dialysis facilities can mature to provide profitability, the
extensive regulation of dialysis operations, government rate determination
for Medicare reimbursement, pricing pressure from private payors, and other
risks detailed in the company's filings with the SEC, particularly as
described in the company's annual report on Form 10-K for the fiscal year
ended December 31, 2008. The historical results contained in this press
release are not necessarily indicative of future performance of the company.

Other Dialysis Corporation of America press releases, corporate profile,
corporate governance materials, quarterly and current reports, and other
filings with the Securities and Exchange Commission are available on Dialysis
Corporation of America's internet home page:
http://www.dialysiscorporation.com.

CONTACT: For additional information, you may contact Dialysis Corporation of
America, 1302 Concourse Drive, Suite 204, Linthicum, MD 21090; Telephone
Number (410) 694-0500; Attention: Investor Relations.

Source: Dialysis Corporation of America